Is there a role for a mucosal influenza vaccine in the elderly?

Drugs and Aging

Volumn 15, Issue 3, 1999, Pages 169-181

  Corrigan, Eilis M ^a   Clancy, Robert L ^b  

^a ROYAL NEWCASTLE HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

AGED; ANTIBODY RESPONSE; DRUG EFFICACY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INTRANASAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; PEYER PATCH; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW;

AGE FACTORS; AGED; ANTIBODIES; CLINICAL TRIALS; DIARRHEA VIRUSES, BOVINE VIRAL; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, BIOLOGICAL;

EID: 0032885520     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915030-00001     Document Type: Review

References (177)

1. Keren G, Segev S, Morag A, et al. Failure of influenza vaccination in the aged. J Med Virol 1988; 25: 85-9
2. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes, reduction in illness and complications during an influenza A (H2N2) epidemic. JAMA 1985; 253: 1136-9
3. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, editor. Options for the control of influenza. New York: Alan R. Liss, 1986: 155-68
4. Nicholson KG. Influenza, Curr Opin Infect Dis 1994; 7: 168-72
5. Nicholson KG. Immunisation against influenza among people aged over 65 living at home in Leicestershire during winter 1991-1992. BMJ 1993; 306: 974-6
6. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123 (7): 518-27
7. Powers, DC, Belshe RB. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody response elicited by inactivated influenza virus vaccine. J Infect Dis 1993; 167: 584-92
8. Feerv BJ, Evered MG, Morrison EI. Antibody responses to influenza virus subunit vaccine in the aged. Med J Aust 1976;: 540-2
9. Hobson D, Curry RL, Beare AS, et al. The role of serum naemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70: 767-77
10. Govaert TM, Sprenger MJW, Dinant GJ, et al. Immune response to influenza vaccination of elderly people: a randomized double-blind placebo-controlled trial. Vaccine 1994; 12: 1185-9
11. Palache AM, Bever WEP, Sprenger MJW, et al. Antibody response after influenza immunization with various vaccine doses: a double blind placebo controlled, multi-centre, dose-response study in elderly nursing home residents and young volunteers. Vaccine 1993; 11: 3-9
12. Masurel N, Laufer J. A one year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg (Lond) 1984; 92: 263-76
13. Beyer WEP, Teunissen MWE, Diepersloot RJA, et al. Immunogenicity and reactogenicity of two doses of trivalent influenza split vaccine: an open randomized study in healthy, unprotected, adult volunteers. J Drug Ther Res 1986; 11: 369-74
14. Mostow SR, Schoenbaum SC, Dowdle WR, et al. Studies with inactivated influenza vaccines purified by zonal centrifugation: I. Adverse reactions and serological responses. Bull World Health Organ 1969; 41: 525-30
15. Strassburg MA, Greenland S, Sorvillo FJ, et al Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38-44
16. Gross PA, Quinnan GV, Weksler ME, et al. Immunisation of elderly people with high doses of influenza vaccine. J Am Genatr Soc 1988; 36: 209-12
17. Beyer WEP, Palache AM, Balijet M, et al. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989; 7: 385-94
18. Voth DW, Feldman HA, Steinschneider A. Comparative responses of elderly persons to aqueous and depot influenza vaccines. Arch Environ Health 1966; 13: 567-85
19. Hobson D, Baker FA, Curry RL. Effects of influenza vaccines in stimulating antibody in volunteers with prior immunity. Lancet 1973; II: 155-7
20. Ligthart GJ, Corberand JX, Fourniet Ch, et al. Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev 1984; 28; 47-55
21. Beyer WEP, Palache AM, Sprenger MJW, et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 1966; 14: 1331-9
22. Pyhala R, Kumpulainen V, Alanko S, et al. H1 antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in (1990) 1992. Vaccine 1994; 12: 947-52
23. Davies JR, Grilli EA. Natural and vaccine induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989; 102: 325-33
24. Hoskins TW, Davis JR, Smith AJ, et al. Assessment of inactivated influenza A vaccine after three outbreaks of influenza at Christ's Hospital. Lancet 1979; 1: 33-5
25. Masurel N, Ophof B, de Jong P. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg (Lond) 1981; 87: 201-9
26. Palache AM. Influenza subunit vaccine: ten years experience. Eur J Clin Res 1992; 3: 117-38
27. Feery BJ, Evered MG, Morrison EI. Different protection rates in various groups of volunteers given subunit influenza vaccine in 1976. J Infect Dis 1979; 39: 237-41
28. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272 (21): 1661-5
29. Nicholson KG, Wiselka MJ, May A. Influenza vaccination of the elderly: perceptions find policies of general practitioners and the outcome of the 1985-86 immunisation programme in Trent, UK. Vaccine 1987; 5: 302-6
30. Kurinczuk U, Nicholson KG. Uptake of influenza vaccination by patients with serious cardiac disease. BMJ 1989; 299: 367
31. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270: 1956-61
32. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1993; 136: 296-306
33. Monto AS, Ohmit SE, Foster DA, et al. Case-control study in Michigan on prevention of hospitalization by vaccination in 1989-1991. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza: II. Amsterdam: Elsevier, 1993; 135-41
34. Barker W, Raubertas R, Menegus M, et al. Case-control study of influenza vaccine effectiveness in preventing pneumonia hospitalization among older persons, Monroe Country, New York 1989-1992. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza: II, Amsterdam: Elsevier, 1993; 143-51
35. Strikas R, Cook P, Kuller L, et al. Case-control study in Ohio and Pennsylvania on prevention of hospitalization of influenza vaccination. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza: II. Amsterdam: Elsevier. 1993; 153-60
36. Nguyen-Van-Tam J, Nicholson K. Influenza immunisation: policies and practices of general practitioners in England 1991/92. Health Trends 1993; 25: 101-5
37. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331 (12): 778-84
38. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivation influenza A virus vaccine. J Clin Microbiol 1986; 23: 66-72
39. McElhaney JE, Meneilly GS, Lechelt KE, et al. Split-virus influenza vaccines: do they provide adequate immunity in the elderly? J Gerontol 1994; 49: M37-43
40. Gorse GJ, Belshe RB, Munn NJ. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 1991; 100: 977-84
41. Yap KL, Ada GL, McKenzie FC. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with live influenza virus. Nature 1978; 273: 238-9
42. Yap KL, Ada GL. Cytotoxic T cells in the lungs of mice infected with influenza A virus. Scand J Immunol 1978; 7: 73-80
43. McMichael AJ, Askonas BA. Influenza virus-specific cytotoxic T cells in man: induction and properties of the cytotoxic cell. Eur J Immunol 1978; 8: 705-11
44. Lamb JR, Eckels DD, Phelan M, et al. Antigen-specific human T lymphocyte clones: viral antigen specificity of influenza virus-immune clones. J Immunol 1982; 128: 1428-32
45. Mitchell DM, Callard RE. Fine specificity of the in vitro antibody response to influenza virus by human blood lymphocytes. J Immunol 1983; 131 (3): 1229-33
46. Clancy RL, Bienenstock J. Enteric infection and immunisation. In: Ferguson A, MacSween RNM, editors. Immunological aspects of the liver and gastrointestinal tract. Lancaster: Medical and Technical Publishing Co. Ltd, 1976: 121-53
47. Bienenstock N, Clancy RL. Bronchial mucosal lymphoid tissue. In: Ogra PL, Lamm ME, McGhee JR, et al., editors. Handbook of mucosal immunology. San Diego (CA): Academic Press, 1994: 529-38
48. Kilian M, Russel MW. Function of mucosal immunoglobulins. In: Ogra PL, Lamm ME, McGhee JR, et al., editors. Handbook of mucosal immunology. San Diego (CA): Academic Press, 1994: 127-37
49. Svanborg C. Bacterial adherence and mucosal immunity. In: Ogra PL, Lamm ME, McGhee JR, et al., editors. Handbook of mucosal immunology. San Diego (CA): Academic Press, 1994: 71-8
50. Mazenec MB, Lamm ME, Lyn, et al. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 1992; 89: 6901-5
51. Kaetzel CS, Robinson JK, Chintalacharuvu KR, et al. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci U S A 1991; 88 (19): 8796-800
52. Taylor HP, Dimmock NJ. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 1985; 161: 198-209
53. Armstrong SJ, Dimmock NJ, Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymerase immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. J Virol 1992; 66: 3823-32
54. Cripps AW, Clancy RL, Murree-Allen K, et al. Quantitation of isotype specific haemophilus influenzac antibody in serum and saliva of normal subjects and chronic bronchitis. Asia Pac J Allergy Immunol 1986; 4: 5-11
55. Gleeson M, Cripps A, Clancy RL. Ontogeny of the secretory immune system in man. Aust N Z J Med 1982; 12: 255-8
56. Brandtzaeg P. Immune functions of human nasal mucosa and tonsils in health and disease. In: Bienenstock J, editor. Immunology of the lung and upper respiratory tract. New York: McGraw Hill, 1984: 28-95
57. Platts-Mills TAE, Ishizaka K. IgG and IgA diphtheria antitoxin responses from human tonsil lymphocytes. J Immunol 1975; 114: 1058-64
58. Zahradnik JM, Karel JA, Martin RR, et al. Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine. J Med Virol 1983; 11: 277-85
59. Murphy BR, Nelson DL, Wright PF, et al. Secretory and systemic immunologic response in children infected with live attenuated influenza A virus vaccine. Infect Immun 1982; 36: 1102-08
60. Burlington DB, Clement ML, Mciklejohn G, et al. Haemagglutinin-specific antibody responses in immunoglobulin G,A and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondly infection of humans with influenza A virus. Infect Immun 1983; 41: 540-5
61. Waldman RH, Henney CS. Cell-mediated immunity and antibody responses in the respiratory tract after local and systemic immunization. J Exp Med 1971; 134: 482-9
62. Clancy RL, Bienenstock J. The proliferative response of bronchus associated lymphoid tissue following local and systemic immunization. J Immunol 1974; 112: 1997-2001
63. Clancy RL, Rawls W, Jagannath S, Appearance of cytotoxic cells within the bronchus following local infection with herpes simplex. J Immunol 1977; 119 (3): 1102-5
64. Buret A, Dunkley M, Clancy RL, et al. The protective role of pulmonary neutrophils in rats intestinally immunized with Pseudomonas. Adv Exp Med Biol 1995; 371B: 765-9
65. Clancy RL, Pucci A. Human mucosal lymphocytes: memory for 'recall' antigens and non-specific suppression by T-lymphocytes. In: McGhee JR, Mestecky J, Babb JL, editors. Secretory immunity and infection in the series. New York: Plenum Press, 1978: 575-82
66. Husband AJ, Dunkley ML, Cripps AW, et al. Antigen-specific response among T lymphocytes following intestinal administration of alloantigens. Aust J Exp Biol Med Sci 1984; 62: 687-99
67. Bender BS, Croghan T, Zhang L, et al. Transgenic mice lacking class 1 major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992; 175: 1143-5
68. Doherty PC, Allan W, Eichelberger M, et al. Roles of alpha beta and gamma delta T cell subsets in viral immunity. Annu Rev Immunol 1991; 10: 123-51
69. Ada GL, Jones PD. The immune response to influenza infection. Curr Top Microbiol Immunol 1986; 128: 1-54
70. Lin Y-L, Askonas BA. Biological properties of an influenza A virus-specific killer T cell clone: inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J Exp Med 1981; 154: 225
71. Taylor PM, Askonas BA. Influenza nucleoprotein specific cytotoxic T cell clones are protective in vivo. Immunology 1986; 58: 417-20
72. Lukacher AE, Braciale VL, Braciale TJ. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 1984; 160: 814-26
73. Scherle PA, Palladino G, Gerhard W, Mice can recover from pulmonary influenza virus infection in the absence of class 1-restricted cytotoxic T cells. J Immunol 1992; 148: 212-17
74. Dolin R, Murphy BR, Caplan EA. Lymphocyte blastogenic responses to influenza virus antigens after influenza infection and vaccination in humans. Infect Immun 1978; 19: 867-74
75. Dowdle WR, Galphin JC, Coleman MT, et al. A simple double immunodiffusion test for typing influenza viruses. Bull World Health Organ 1974; 51: 213-5
76. Schild GC. Evidence for a new type-specific structural antigen of the influenza virus particle. J Gen Virol 1972; 15: 99-103
77. Schild GC, Pereira HG. Characterisation of the ribonucleoprotein and neuraminidase of influenza A virus by immunodiffusion. J Gen Virol 1969; 4: 355-63
78. Craig SW, Cebra JJ. Peyer's patches: an enriched source of precursors for IgA-producing immunocytes in the rabbit. J Exp Med 1971; 134: 188
79. Rudzik O, Clancy RL, Percy DYE, et al. Repopulation with IgA containing cells of bronchial and intestinal lamina propria after transfer of homologous Peyer's patches and bronchial lymphocytes. J Immunol 1975; 114: 40-4
80. Bienenstock J, Johnston N, Perey DYE. Bronchial lymphoid tissue: I. Morphologic characteristics. Lab Invest 1973; 28: 686-92
81. Sciechitano R, Husband AJ, Clancy RL. Contribution of gut immunisation to the local immune response in the respiratory tract of sheep. Immunology 1984; 53: 375-84
82. Kawanishi H, Sulzman LE, Strober W. Mechanisms regulating IgA class-specific immunoglobulin production in murine gut-associated lymphoid tissues: I. J Exp Med 1983; 157: 433-50
83. Kawanishi H, Sulzman LE. Strober W. Mechanisms regulating IgA class-specific immunogiobulin production in murine gut-associated lymphoid tissues: II. J Exp Med 1983; 158: 649-69
84. Kivono H, McGhee JR, Mosteller LM, et al. Murine Payer's patch T cell clones. J Exp Med 1982; 156: 1115-30
85. Kivono H, Cooper MD, Kearney JF, et al. Isotype specificity of helper T-cell clones. J Exp Med 1984; 159: 798-811
86. Dunkley ML, Husband AJ, Undertown BJ. Cognate T-cell help in the induction of IgA responses in vivo. Immunology 1990; 71: 16-9
87. Husband AJ, Gowans JL. The origin and antigen-dependent distribution of IgA-containing cells in the intestine. J Exp Med 1978; 148: 1146-60
88. Mestecky J, McGhee JR. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987; 40: 153-245
89. Brandtzaeg P. Overview of the mucosal immune system. Curr Top Microbiol Immunol 1989; 146: 13-25
90. Quillan Jr JJ, Francis T. Serological response to intranasal administration of inactive influenza virus in children. J Clin Invest 1947; 26: 1079-87
91. Kasal JA, Hume EB, Fulk RV, et al. Antibody response in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine. J Immunol 1969; 102: 555-62
92. Fulk RV, Fedson DS, Hubert MA, et al. Antibody responses in children and elderly persons following local or parenteral administation of an inactivated influenza virus vaccine: A/Hong Kong/68 variant. J Immunol 1969; 102: 1102-5
93. Walderman RH, Kasal JA, Fulk RV, et al. Influenza antibody in human respiratory secretions after subcutaneous or respiratory immunization with inactivated virus. Nature 1968; 218: 594-5
94. Walderman RH, Mann JJ, Small Jr PA, et al. Immunization against influenza: prevention of illness in man by aerosolized inactivated vaccine. JAMA 1969; 207: 520-4
95. 2Hong Kong/68 inactivated influenza/a virus. J Immunol 1970; 104: 8-13
96. Liew FY, Russell SM. Appleyard G, et al. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol. 1984; 14: 350-6
97. Donabedian AM, DeBorde DC, Maassab HF. Genetics of cold-adapted B/Ann Arbor/I/66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence. Microb Pathog 1987; 3: 97-108
98. Belshe RB, Van Voris LP, Bartram J, et al, Live attenuated influenza A virus vaccines in children: results of a field trial. J Infect Dis 1984; 150: 834-40
99. Edwards KM, King JC, Steinhoff MC, et al. Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children. J Infect Dis 1991; 163: 740-5
100. Belshe RB, Swierkosz EM, Anderson EL, et al. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H2N2, and B vaccine. J Infect Dis 1992; 165: 727-32
101. Gruber WC, Kirschner K, Tollefson S, et al. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children. J Infect Dis 1993; 168: 53-60
102. Clements ML, Betts REF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984; 1: 705-8
103. Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of attenuated and inactivated influenza vaccines in school children and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993; 168: 881-7
104. Kuno-Sakai H, Kimura M, Ohta K, et al. Developments in mucosal influenza virus vaccines. Vaccine 1994; 12: 1303-10
105. Johnson PR, Feldman S, Thompson JM, et al. Comparison of long-term systemic and secretory antobody responses in sero-negative children given live, attenuated or inactivated influenza A vaccine. J Med Virol 1985; 17: 325-35
106. Couch RB, Kasal JA, Six HR, et al. The basis for immunity to influenza in man. In: Nayak DP, Fox DF, editors. Genetic variation among influenza viruses. New York: Academic Press, Inc., 1981; 535-46
107. Puck JM, Glezen WP, Frank AL, et al. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J Infect Dis 1980; 142: 844-9
108. Ramphal R, Cogliano RC, Sahnds JW, et al. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun 1980; 25: 992-7
109. Cate TR, Couch RB, Kasal JA, et al. Clinical trials of monovalent influenza A: New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence. J Infect Dis 1977; 136 Suppl.: 450-5
110. Clark A, Potter CW, Jennings R, et al. A comparison of live and inactivated influenza A (H1N1) virus vaccines: 2. Long term immunity. J Hyg (Lond) 1983; 90: 361-70
111. Wright PF, Okabe KT, McKee Jr KT, et al. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982; 146: 71-9
112. Powers DC, Sears SD, Murphy BR, et al. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989; 27: 2666-71
113. Gorse GJ, Belshe RB, Munn NJ. Safety of and serum antobody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic disease. J Clin Microbiol 1986; 24: 336-42
114. Wright PR, Murphy BR, Kervina M, et al. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun 1983; 40: 1092-5
115. Tamura S, Samegai Y, Kurata H, et al. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 1988; 6 (5): 409-13
116. Tamura S, Ito Y, Asanuma H, et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 1992; 149: 981-8
117. Kimura M, Saka H, Takesue R, et al. Intranasal administration of influenza inactivated HA vaccine. Clin Virol 1987; 15: 407
118. Hashigucci K, Ogawa H, Ishidate T, et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 1996; 14: 113-9
119. Higaki M, Takase T, Igarashi R, et al. Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin. Vaccine 1998; 16: 741-5
120. Kreuter J, Berg U, Soliva M, et al. Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants. Vaccine 1986; 4: 125-9
121. Treanor JJ, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117: 625-33
122. Bloom L, Rowley D. Local immune response in mice to V. Cholerae. Aust J Exp Biol Med Sci 1979; 57: 313
123. Forrest BD, Labrooy JT, Dearlove CE, et al. Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a. Infect Immun 1992; 60: 465-71
124. Bergmann KC, Waldman RH. Occurrence of influenza specific antibodies in the lung after oral immunization in mice. Poumon Coeur 1982; 38: 289-92
125. Bergmann KC, Waldman RH, Veltri RW. Oral immunization using influenza virus II respiratory secretion antibody and protection in mice. Am Rev Respir Dis 1982; 125 (4 Suppl.): 67
126. Bergmann KC, Lachmann B, Noack K. Lung mechanics in orally immunized mice after aerolized exposure to influenza virus. Respiration 1984; 46: 218-21
127. Bergmann KC, Waldman RH. Antibodies against influenza and stimulated macrophages in the lung lavage fluid of mice following oral immunization. Allerg Immunol (Leipz) 1983; 29: 215-22
128. Waldman RH, Bergmann KC, Stone J, et al. Age dependent antibody response in mice and humans following oral influenza immunization. J Clin Immunol 1987; 7: 327-32
129. Tischner H, Pohl WD, Bergmann KC, et al. Orale immunisierung gegen influenza bei kindern mit chronischen atemtrakterkrankungen. Z Klin Med 1985; 40: 1989-92
130. Waldman RH, Stone J, Lazzell VA, et al. Regulation of the immune response to orally administered antigens. 8th International Congress on Immunology: 1982; Amherst (NY). Basel: Karger, 1983: 186-94
131. Clancy RL, Cripps AW, Husband AJ, et al. Specific immune response in the respiratory tract following an oral polyvalent bacterial vaccine. Infect Immun 1983; 39 (2): 491-6
132. Cornes JS. Number, size and distribution of Peyer's patches in the human small intestine. Gut 1965; 6: 225-33
133. Moldoveanu Z, Novak M, Huang W-Q, et al. Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 1993; 167: 84-90
134. Bland PW, Warren LG. Antigen presentation by epithelial cells of the rat small intestine. Immunology 1986; 58: 9-14
135. Michalck SM, Childers NK, Katz J, et al. Liposomes as oral adjuvants. Curr Top Microbiol Immunol 1989; 146: 51-8
136. Jackson S, Mestecky J, Childers NK, et al. Liposomes containing anti-idiotypic antibodies: an oral vaccine to induce protective secretory immune responses specific for pathogens of mucosal surfaces. Infect Immun 1990; 58: 1932-6
137. Guzman CA, Molinari G, Fountain MW, et al. Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid. Infect Immun 1993; 61 (2): 573-9
138. Eldridge JH, Gilley RM, Staas JK, et al. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbiol Immunol 1989; 146: 59-66
139. Eldridge JH, Hammond CJ, Meulbroek JA, et al. Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administered biodegradable microcapsules target the Peyer's patches. J Controlled Release 1990; 11: 205-14
140. Challacombe SJ, Rahman D, Jeffery H, et al. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 1992; 76: 164-8
141. O'Hagan DT, McGhee JP, Holmgren J, et al. Biodegradable microparticles for oral immunization. Vaccine 1993; 11: 149-54
142. Santiago N, Milstein S, Rivera T, et al. Oral immunization of rats with proteinoid microspheres encapsulating influenza virus antigens. Pharm Res 1993; 10: 1243-7
143. Heritage PL, Loomes LM, Jianxiong J, et al. Novel polymer-grafted starch microparticles for mucosal delivery of vaccines. Immunology 1996; 88: 162-8
144. Mowat AM, Donachie AM, Reid G, et al. Immune-stimulating complexes containing quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991; 72: 317-22
145. Mowat AM, Maloy KJ, Donachie AM. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 1993; 80: 527-34
146. Mannino RJ. Protein cochleate vaccines. Vaccine 1989; 147-51
147. Ekman B, Sjoholm I. Improved stability of proteins immobilized in microparticles prepared by a modified emulsion polymerisation technique. J Pharm Sci 1978; 67: 693-6
148. Pappo J, Ermak TM, Steger HJ. Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology 1991; 73: 277-80
149. Eldridge JH, Staas JK, Meulbroek JA, et al. Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991; 28: 287-94
150. O'Hagan DT, Jeffery H, Roberts MJJ, et al. Controlled release microparticles for vaccine development. Vaccine 1991; 9: 768-71
151. Loh D, Ross AM, Hale AH, et al. Synthetic phospholipid vesicles containing a purified viral antigen and cell membrane proteins stimulate the development of cytotoxic T lymphocytes. J Exp Med 1979; 150(5): 1067-74
152. Nerome K, Yoshioka Y, Ishida M, et al. Development of a new type of influenza subunit vaccine made by muramyldipeptide liposomes: enhancement of humoral and cellular immune responses. Vaccine 1990; 8: 504-9
153. Lomotan EA, Brown KA, Speaker TJ, et al. Aqueous-based microcapsules are detected primarily in gut-associated dendritic cells after oral inoculation of mice. Vaccine 1997; 15: 1959-62
154. Liu LM, MacPherson GG. Lymph-borne (veiled) dendritic cells can acquire and present intestinally administered antigens. Immunology 1991; 73: 281-6
155. Guery JC, Adorini L. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II restricted T cells. J Immunol 1995; 154: 536-44
156. Van Vugt E, Verdaasdonk MAM, Kamperdijk EWA, et al. Antigen presenting capacity of peritoneal macrophages and dendritic cells. In: Kamperdijk EWA, editor. Dendritic cells in fundamental and clinical immunology. New York: Plenum Press, 1993
157. Bhardwaj N, Young JW, Nisanian AJ, et al. Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses. J Exp Med 1993; 178: 633-42
158. Liu LM, MacPherson GG. Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo. J Exp Med 1993; 177: 1299-307
159. Moser CA, Speaker TJ, Offit PA. Effect of microencapsulation on immunogenicity of a bovine herpes virus glycoprotein and inactivated influenza virus in mice. Vaccine 1997; 15: 1767-72
160. Moldoveanu Z, Staas JK, Gilley, RM, et al. Immune responses to influenza virus in orally and systemically immunized mice. Curr Top Microbiol Immunol 1989; 46: 91-9
161. Pang G, Clancy RL, O'Reilly S, et al. A novel particulate influenza virus vaccine stimulates durable and broad-based protection in mice following oral immunisation. J Virol 1992; 66 (2): 1162-70
162. Tomasi TB, Bienenstock J. Secretory immunoglobulins. In: Dixon FJ, Kunkel HG, editors. Advances in immunology. New York: Academic Press Inc., 1968: 1-96
163. Heremans JF. Immunoglobulin formation and function in different tissues. Curr Top Microbiol Immunol 1968; 45: 131
164. Byleveld PM, Pang GT, Clancy RL, et al. Virus specific and polyclonal responses following challenge with influenza in immunised mice fed fish oil, linseed oil or beef tallow. J Nutrition. In press
165. Wells MA, Daniel S, Djen JY, et al. Recovery from a viral respiratory tract infection: IV. Specificity of protection by cytotoxic T lymphocytes. J Immunol 1983: 130 (6): 2908-14
166. Butt HL, Clancy RL, Cripps AW, et al. Bacterial colonisation of the respiratory tract in chronic bronchitis. Aus N Z J Med 1990; 20: 35-8
167. Scheiblauer H, Reinacher M, Tashiro M, et al. Interactions between bacteria and influenza A virus in the development of influenza pneumonia. J Infect Dis 1992; 166: 783-91
168. Heikkinen T, Waris M, Ruuskanen O. Efficacy of influenza vaccination in reducing otitis media in children. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza II. Amsterdam: Elsevier, 1993: 431-4
169. Walker JA, Kawaoka Y. Importance of conserved amino acids at the cleavage site of a virulent avian influenza A virus. J Gen Virol 1993; 74: 311-4
170. Dunkley M, Clancy R. A rodent model of concurrent respiratory infection with influenza virus and gram negative bacteria: synergistic infection and protection by oral immunization. Immunol Cell Biol 1997; 75 (1): A7
171. Clancy R, Cripps, A, Murree-Allen K. et al. Protection against acute bronchitis in chronic obstructive lung disease induced by oral immunization with killed haemophilus influenzae. Lancet 1985; II: 1395-7
172. Lehmann D, Coakley KH, Coakley CA, et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. Am Rev Respir Dis 1991; 144: 324-30
173. Clancy RL, Cripps AW. Specific protection against acute bronchitis associated with non-typable Haemophilus influenzae. J Infect Dis 1992; 165 Suppl. 1: 5194-5
174. Moldoveanu Z, Clements ML, Prince SJ, et al. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995; 13 (11): 1006-12
175. Gorse GJ, Otto EE, Daughaday CC, et al. Influenza virus vaccination of patients with chronic lung disease. Chest 1997; 112: 1221-33
176. Gorse GJ, Campbell MH, Otto EE, et al. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis 1995; 172: 1-10
177. Gorse GJ, Belshe RB. Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol 1990; 28: 2539-50